NT‑ProBNP levels are moderately increased in acute high‑altitude pulmonary edema

Gao,Mingdong; Wang,Ruimin; Jiayong,Zepei; Liu,Yin; Sun,Genyi

doi:10.3892/etm.2013.976

NT‑ProBNP levels are moderately increased in acute high‑altitude pulmonary edema

Authors:
- Mingdong Gao
- Ruimin Wang
- Zepei Jiayong
- Yin Liu
- Genyi Sun
View Affiliations

Affiliations: Department of Cardiology, Tianjin Chest Hospital, Tianjin 30051, P.R. China, Department of Clinical Laboratory, Affiliated Hospital of Logistics University of Chinese People's Armed Police Forces, Tianjin 300162, P.R. China, Changdu District People's Hospital, Tibet 854000, P.R. China
Published online on: February 26, 2013 https://doi.org/10.3892/etm.2013.976
Pages: 1434-1438

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the effect of B‑type natriuretic peptides (BNPs) in acute high‑altitude pulmonary edema (HAPE). The study enrolled 46 subjects from lowland Han, including 33 individuals who had acutely ascended to a high altitude (21 individuals with HAPE as the case group and 12 individuals without HAPE as the high‑altitude control group) and 13 healthy normal residents as the plain control group. The serum concentrations of N-terminal probrain natriuretic peptide (NT‑proBNP), erythropoietin (EPO), vascular endothelial growth factor (VEGF) and nitric oxide (NO) were measured. There were significant differences in the serum concentrations of NT‑ProBNP, NO, VEGF and EPO among the three groups. The serum concentrations of NT‑ProBNP, EPO and VEGF were significantly higher in the HAPE patients and high‑altitude control individuals than those of the plain group. No significant differences were identified between the HAPE patients and the high‑altitude control group. In contrast to these three parameters, the serum concentrations of NO in the high‑altitude control group were significantly higher than those of the HAPE patients and the plain group, while there were no significant differences in the serum concentrations of NO between the HAPE patients and the plain group. Furthermore, serum concentrations of NT‑ProBNP and EPO were significantly reduced following treatment in the HAPE patients, however, no significant changes were identified in VEGF or NO concentrations. BNPs are increased in HAPE with severe hypoxia and right ventricular overload, but are decreased subsequent to treatment. BNPs may therefore be a potential biomarker for the diagnosis and prognosis of HAPE.

View Figures

View References

1.	Scherrer U, Rexhaj E, Jayet PY, Allemann Y and Sartori C: New insights in the pathogenesis of high-altitude pulmonary edema. Prog Cardiovasc Dis. 52:485–492. 2010. View Article : Google Scholar : PubMed/NCBI
2.	Duplain H, Vollenweider L, Delabays A, Nicod P, Bärtsch P and Scherrer U: Augmented sympathetic activation during short-term hypoxia and high-altitude exposure in subjects susceptible to high-altitude pulmonary edema. Circulation. 99:1713–1718. 1999. View Article : Google Scholar : PubMed/NCBI
3.	Duplain H, Sartori C, Lepori M, et al: Exhaled nitric oxide in high-altitude pulmonary edema: role in the regulation of pulmonary vascular tone and evidence for a role against inflammation. Am J Respir Crit Care Med. 162:221–224. 2000. View Article : Google Scholar : PubMed/NCBI
4.	Bailey DM, Dehnert C, Luks AM, et al: High-altitude pulmonary hypertension is associated with a free radical-mediated reduction in pulmonary nitric oxide bioavailability. J Physiol. 588:4837–4847. 2010. View Article : Google Scholar : PubMed/NCBI
5.	Pham I, Wuerzner G, Richalet JP, et al: Endothelin receptors blockade blunts hypoxia-induced increase in PAP in humans. Eur J Clin Invest. 40:195–202. 2010. View Article : Google Scholar : PubMed/NCBI
6.	Sartori C, Vollenweider L, Löffler BM, et al: Exaggerated endothelin release in high-altitude pulmonary edema. Circulation. 99:2665–2668. 1999. View Article : Google Scholar : PubMed/NCBI
7.	Christou H, Yoshida A, Arthur V, Morita T and Kourembanas S: Increased vascular endothelial growth factor production in the lungs of rats with hypoxia-induced pulmonary hypertension. Am J Respir Cell Mol Biol. 18:768–776. 1998. View Article : Google Scholar : PubMed/NCBI
8.	Nakanishi K, Tajima F, Itoh H, et al: Changes in atrial natriuretic peptide and brain natriuretic peptide associated with hypobaric hypoxia induced pulmonary hypertension in rats. Virchows Arch. 439:808–817. 2001. View Article : Google Scholar : PubMed/NCBI
9.	Weidemann A, Klanke B, Wagner M, et al: Hypoxia, via stabilization of the hypoxia-inducible factor HIF-1alpha, is a direct and sufficient stimulus for brain-type natriuretic peptide induction. Biochem J. 409:233–242. 2008. View Article : Google Scholar : PubMed/NCBI
10.	Klinger JR, Thaker S, Houtchens J, Preston IR, Hill NS and Farber HW: Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension. Chest. 129:417–425. 2006. View Article : Google Scholar : PubMed/NCBI
11.	McGrath MF, de Bold ML and de Bold AJ: The endocrine function of the heart. Trends Endocrinol Metab. 16:469–477. 2005. View Article : Google Scholar : PubMed/NCBI
12.	Kishimoto I, Tokudome T, Horio T, Garbers DL, Nakao K and Kangawa K: Natriuretic peptide signaling via guanylyl cyclase (GC)-A: an endogenous protective mechanism of the heart. Curr Cardiol Rev. 5:45–51. 2009. View Article : Google Scholar : PubMed/NCBI
13.	Hackett PH and Oelz O: The Lake Louise consensus on the definition and quantification of altitude illness. Mountain Medicine Hypoxia. Sutton JR, Houston CS and Coates G: VT: Queen City Printers; Burlington: pp. 327–330. 1992
14.	Ge RL, Mo VY, Januzzi JL, et al: B-type natriuretic peptide, vascular endothelial growth factor, endothelin-1, and nitric oxide synthase in chronic mountain sickness. Am J Physiol Heart Circ Physiol. 300:H1427–H1433. 2011. View Article : Google Scholar : PubMed/NCBI
15.	Palazzuoli A, Calabria P, Vecchiato L, et al: Plasma brain natriuretic peptide levels in coronary heart disease with preserved systolic function. Clin Exp Med. 4:44–49. 2004. View Article : Google Scholar : PubMed/NCBI
16.	Casals G, Ros J, Sionis A, Davidson MM, Morales-Ruiz M and Jiménez W: Hypoxia induces B-type natriuretic peptide release in cell lines derived from human cardiomyocytes. Am J Physiol Heart Circ Physiol. 297:H550–H555. 2009. View Article : Google Scholar : PubMed/NCBI
17.	Xia WJ, Huang YY, Chen YL, Chen SL and He JG: Acute myocardial ischemia directly modulates the expression of brain natriuretic peptide at the transcriptional and translational levels via inflammatory cytokines. Eur J Pharmacol. 670:7–12. 2011. View Article : Google Scholar
18.	Lemus-Varela ML, Flores-Soto ME, Cervantes-Munguía R, et al: Expression of HIF-1 alpha, VEGF and EPO in peripheral blood from patients with two cardiac abnormalities associated with hypoxia. Clin Biochem. 43:234–239. 2010. View Article : Google Scholar : PubMed/NCBI
19.	Steiner J and Guglin M: BNP or NT-proBNP? A clinician’s perspective. Int J Cardiol. 129:5–14. 2008.
20.	Kaufmann BA, Bernheim AM, Kiencke S, et al: Evidence supportive of impaired myocardial blood flow reserve at high-altitude in subjects developing high-altitude pulmonary edema. Am J Physiol Heart Circ Physiol. 294:H1651–H1657. 2008. View Article : Google Scholar : PubMed/NCBI
21.	Mahmud E, Raisinghani A, Hassankhani A, et al: Correlation of left ventricular diastolic filling characteristics with right ventricular overload and pulmonary artery pressure in chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol. 40:318–324. 2002. View Article : Google Scholar
22.	Allemann Y, Rotter M, Hutter D, et al: Impact of acute hypoxic pulmonary hypertension on LV diastolic function in healthy mountaineers at high altitude. Am J Physiol Heart Circ Physiol. 286:H856–H862. 2004. View Article : Google Scholar : PubMed/NCBI
23.	Mason NP, Petersen M, Melot C, et al: Serial changes in nasal potential difference and lung electrical impedance tomography at high-altitude. J Appl Physiol. 94:2043–2050. 2003. View Article : Google Scholar : PubMed/NCBI
24.	Toshner MR, Thompson AA, Irving JB, et al: NT-proBNP does not rise on acute ascent to high-altitude. High Alt Med Biol. 9:307–310. 2008. View Article : Google Scholar : PubMed/NCBI
25.	Feddersen B, Ausserer H, Haditsch B, Frisch H, Noachtar S and Straube A: Brain natriuretic peptide at altitude: relationship to diuresis, natriuresis, and mountain sickness. Aviat Space Environ Med. 80:108–111. 2009. View Article : Google Scholar : PubMed/NCBI
26.	Woods D, Hooper T, Hodkinson P, et al: Effects of altitude exposure on brain natriuretic peptide in humans. Eur J Appl Physiol. 111:2687–2693. 2011. View Article : Google Scholar : PubMed/NCBI
27.	Woods DR, Begley J, Stacey M, Smith C, Boos CJ, Hooper T, Hawkins A, Hodkinson P, Green N and Mellor A: Severe acute mountain sickness, brain natriuretic peptide and NT-proBNP in humans. Acta Physiol (Oxf). 205:349–355. 2012. View Article : Google Scholar : PubMed/NCBI
28.	Yoshimura M, Yasue H and Ogawa H: Pathophysiological significance and clinical application of ANP and BNP in patients with heart failure. Can J Physiol Pharmacol. 79:730–735. 2001. View Article : Google Scholar : PubMed/NCBI
29.	Leuchte HH, Holzapfel M, Baumgartner RA, Neurohr C, Vogeser M and Behr J: Characterization of brain natriuretic peptide in long-term follow-up of pulmonary arterial hypertension. Chest. 128:2368–2374. 2005. View Article : Google Scholar : PubMed/NCBI
30.	McGrath MF, de Bold ML and de Bold AJ: The endocrine function of the heart. Trends Endocrinol Metab. 16:469–477. 2005. View Article : Google Scholar : PubMed/NCBI